Stock NAII NATURAL ALTERNATIVES INTERNATIONAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Natural Alternatives International, Inc.

Equities

NAII

US6388423021

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
6.25 USD -3.40% Intraday chart for Natural Alternatives International, Inc. -6.44% -4.29%
Apr. 02 Natural Alternatives International Scheduled to Reopen U.S. Manufacturing Facility in California to Support Increased Production Needs CI
Feb. 15 CarnoSyn®? Brands Partners with Barentz for Exclusive Brazilian Distribution of CarnoSyn®? Beta-Alanine CI

Valuation

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Capitalization 1 75.4 87.72 43.81 104.7 63.57 43.74
Enterprise Value (EV) 1 51.79 62.68 42.11 89.05 73.58 61.07
P/E ratio 13.9 x 12.7 x -27.4 x 9.96 x 6 x 16.7 x
Yield - - - - - -
Capitalization / Revenue 0.57 x 0.63 x 0.37 x 0.59 x 0.37 x 0.28 x
EV / Revenue 0.39 x 0.45 x 0.35 x 0.5 x 0.43 x 0.4 x
EV / EBITDA 3.38 x 5.3 x 9.46 x 4.64 x 4.12 x 6.81 x
EV / FCF -8.96 x 296 x 15.3 x 6.15 x -3.94 x -15.6 x
FCF Yield -11.2% 0.34% 6.53% 16.3% -25.4% -6.42%
Price to Book 1.07 x 1.05 x 0.63 x 1.34 x 0.72 x 0.49 x
Nbr of stocks (in thousands) 7,429 7,523 6,404 6,221 6,089 6,076
Reference price 2 10.15 11.66 6.840 16.83 10.44 7.200
Announcement Date 9/19/18 9/24/19 9/21/20 9/20/21 9/21/22 9/21/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net sales 1 132.4 138.3 118.9 178.5 171 154
EBITDA 1 15.34 11.83 4.45 19.21 17.84 8.963
EBIT 1 12.43 8.361 0.491 14.87 13.68 4.713
Operating Margin 9.39% 6.05% 0.41% 8.33% 8% 3.06%
Earnings before Tax (EBT) 1 10.61 7.953 -1.738 12.12 13.66 3.555
Net income 1 5.051 6.541 -1.645 10.77 10.71 2.522
Net margin 3.81% 4.73% -1.38% 6.03% 6.27% 1.64%
EPS 2 0.7300 0.9200 -0.2500 1.690 1.740 0.4300
Free Cash Flow 1 -5.778 0.2115 2.751 14.48 -18.67 -3.923
FCF margin -4.36% 0.15% 2.31% 8.11% -10.92% -2.55%
FCF Conversion (EBITDA) - 1.79% 61.82% 75.37% - -
FCF Conversion (Net income) - 3.23% - 134.47% - -
Dividend per Share - - - - - -
Announcement Date 9/19/18 9/24/19 9/21/20 9/20/21 9/21/22 9/21/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - 10 17.3
Net Cash position 1 23.6 25 1.7 15.7 - -
Leverage (Debt/EBITDA) - - - - 0.5609 x 1.933 x
Free Cash Flow 1 -5.78 0.21 2.75 14.5 -18.7 -3.92
ROE (net income / shareholders' equity) 7.81% 9.06% -2.23% 14.2% 12.7% 2.85%
ROA (Net income/ Total Assets) 9.85% 5.85% 0.29% 7.73% 6.42% 2.1%
Assets 1 51.29 111.8 -572.8 139.3 166.8 119.9
Book Value Per Share 2 9.480 11.10 10.90 12.60 14.40 14.60
Cash Flow per Share 2 3.280 3.660 4.650 5.040 3.560 2.240
Capex 1 4.08 5.33 4.54 5.11 26.5 13.5
Capex / Sales 3.08% 3.85% 3.82% 2.86% 15.49% 8.78%
Announcement Date 9/19/18 9/24/19 9/21/20 9/20/21 9/21/22 9/21/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
NATURAL ALTERNATIVES INTERNATIONAL, INC. Stock Natural Alternatives International, Inc.
-4.29% 38.06M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. NAII Stock
  4. Financials Natural Alternatives International, Inc.